Khaitan Chemical

The stock that fell off a cliff and is now brushing the dust off

Start with the number that jumps out of the page: this share traded at ₹136 within the last twelve months and now changes hands at ₹47.8. That is a fall of roughly fifty-five percent in a single year, and the price is sitting a whisker above its 52-week low of ₹42.8. Most investors run from a chart that looks like this. We slow down and ask a plainer question — did the *business* fall off a cliff, or only the mood around it?

What Khaitan actually does

Picture the humble sack of fertilizer a farmer heaves onto his shoulder before the monsoon. Khaitan Chemicals & Fertilizers, going since 1982, makes one of the everyday workhorses inside that sack — Single Super Phosphate — along with sulphuric acid, which is the industrial vinegar that half the chemical world needs to get anything done. Think of the company as the fellow who sells umbrellas and raincoats: when the season is right and the rains come, everybody wants his goods; when a season goes wrong, his stall sits quiet and his ledger bleeds. This is not a smooth, subscription-like business. It breathes in and out with crop cycles, government subsidy timing, and the price of raw materials it cannot control.

The breathing shows up brutally in the profit line. Look at the arc: ₹80 crore of net profit in FY22, then ₹42 crore, then a thumping *loss* of ₹70 crore in FY24, a near-zero ₹1 crore in FY25, and now a snap back to ₹65 crore in FY26 with trailing profit of ₹54 crore. That FY24 hole is why the three-year return on equity reads minus one percent — a single bad year dragging the average into the mud. The last twelve months tell a different story: return on equity of 25.4 percent and return on capital of 18.5 percent. Both figures are respectable. The trick is knowing whether you are catching the good breath or the bad one.

The turn in the numbers

Sales are what interest me most here. Revenue was stuck in the ₹350–480 crore range for years, then jumped to ₹824 crore in FY22, wobbled down to ₹536 crore in the loss year, and has now climbed to ₹1,002 crore in FY26 — the highest in the company's history. Trailing sales run at ₹988 crore, growing twenty percent over the past year. The five-year compounded sales growth of sixteen percent is genuine; the ten-year figure of ten percent tells you the older years were sleepier. Profit has grown at twenty-one percent compounded over five years, though from a small and jumpy base.

Now the detail I always hunt for, because it separates honest compounders from serial fund-raisers: the equity capital has sat frozen at ₹10 crore for eleven straight years. No dilution, not a rupee of it. When this company earned money, the existing owners kept every slice of it — they did not print fresh shares to paper over the FY24 loss. That is a mark of discipline, and in a cyclical business it matters even more, because the temptation to raise capital at the bottom is strongest exactly when you should resist it. Debtor days have tightened from thirty-one to under twenty-three, so the working-capital housekeeping is improving too.

What you pay and what to fear

The stock trades at a price-to-earnings of just under eight. Its own five-year and ten-year median sit at 15.4. So you are buying at roughly a forty-eight percent discount to how the market has habitually valued this very business. Book value is ₹30 against a price of ₹47.8, so a shade over 1.5 times its own net worth. On the surface, cheap.

But I will not dress up the risks, because this is a *short* trade, not a marriage. First, cyclicality: the earnings on which that P/E rests are trailing earnings caught, perhaps, near a good part of the cycle — one more FY24-style year and the multiple stops looking generous. Second, Screener flags a low tax rate, and a low tax rate on a fertilizer company can mean subsidy accounting and timing effects that inflate a single year's profit; treat FY26's ₹65 crore with a raised eyebrow, not a hug. Third, promoters have trimmed their stake from 75 percent to 72.65 percent — modest, but a nibble, not an add. The dividend yield of 0.10 percent is a rounding error; do not come here for income.

The verdict for a one-to-six-month hand

This is a beaten-down cyclical trading well below its normal valuation, with record sales, a clean unchanged share count, and a fresh profit rebound — bought by momentum-minded hands hoping the market catches up to the recovering earnings before the next down-breath arrives. The margin of safety is in the price you pay relative to book and to its own history, not in the steadiness of the business, because there is none. Size the position for a stock that has already halved once and can halve again if the cycle sours. Keep your stop honest, your horizon short, and your expectations for this fertilizer sack exactly as seasonal as the crop it feeds.